US10227406B2 – March 12, 2019 – Cannabinoid receptor-1 (CB1) monoclonal antibodies

Please complete the required fields.




Inventors :

Peter Coward; Steven A. Moore, Jr.; Shi-Yuan Meng; Mei-Mei Tsai; Chadwick Terence King; Aaron Avraham Nazarian

Owner :

AMGEN INC., CALIFORNIA

Application Number :

US14899551

Document Number :

US10227406B2

Priority Date :

June 25, 2014

Filing Date :

June 25, 2014

Date of Grant/ Publication :

March 12, 2019

Class :

C07K16 / 28

Abstract

This disclosure relates to CB1 receptor antigen-binding proteins, e.g. antibodies and methods of using the CB1 receptor antibodies. The CB1 receptor antibodies may comprise an antagonistic antibody to CB1 receptors and may be used to treat various health conditions. The health conditions can comprise obesity or diabetes or any disease that benefits from antagonism of the CB1 receptor.

Claim(s)

1. A monoclonal antibody or antigen-binding fragment wherein the antibody or antigen-binding fragment thereof comprises a heavy chain variable region comprising complementarity determining regions (CDRs) designated H1, H2, and H3 and a light chain variable region comprising CDRs designated L1, L2, and L3, wherein H1, H2, and H3 have the sequence of SEQ ID NO: 17, 18, and 19, respectively, and L1, L2, and L3 have the sequence of SEQ ID NO: 20, 21, and 22, respectively.;
16. A method for improving a metabolic parameter in a subject in need thereof comprising administering to the subject an antibody or antigen-binding fragment thereof of claim wherein one or more metabolic parameters is improved in the subject following administration of the antibody or antigen-binding fragment thereof.

Summary

No Comments

Leave a comment

Sorry, you must be logged in to post a comment. Login